全文获取类型
收费全文 | 31790篇 |
免费 | 1855篇 |
国内免费 | 99篇 |
专业分类
耳鼻咽喉 | 252篇 |
儿科学 | 1093篇 |
妇产科学 | 923篇 |
基础医学 | 3578篇 |
口腔科学 | 397篇 |
临床医学 | 5831篇 |
内科学 | 5307篇 |
皮肤病学 | 343篇 |
神经病学 | 3122篇 |
特种医学 | 601篇 |
外国民族医学 | 1篇 |
外科学 | 3069篇 |
综合类 | 296篇 |
现状与发展 | 1篇 |
一般理论 | 50篇 |
预防医学 | 4441篇 |
眼科学 | 443篇 |
药学 | 1848篇 |
中国医学 | 33篇 |
肿瘤学 | 2115篇 |
出版年
2023年 | 184篇 |
2022年 | 254篇 |
2021年 | 592篇 |
2020年 | 424篇 |
2019年 | 650篇 |
2018年 | 806篇 |
2017年 | 559篇 |
2016年 | 637篇 |
2015年 | 670篇 |
2014年 | 988篇 |
2013年 | 1591篇 |
2012年 | 2295篇 |
2011年 | 2427篇 |
2010年 | 1293篇 |
2009年 | 1127篇 |
2008年 | 2197篇 |
2007年 | 2394篇 |
2006年 | 2279篇 |
2005年 | 2216篇 |
2004年 | 2038篇 |
2003年 | 1956篇 |
2002年 | 1870篇 |
2001年 | 222篇 |
2000年 | 182篇 |
1999年 | 284篇 |
1998年 | 371篇 |
1997年 | 310篇 |
1996年 | 246篇 |
1995年 | 275篇 |
1994年 | 215篇 |
1993年 | 210篇 |
1992年 | 134篇 |
1991年 | 137篇 |
1990年 | 135篇 |
1989年 | 111篇 |
1988年 | 103篇 |
1987年 | 94篇 |
1986年 | 92篇 |
1985年 | 105篇 |
1984年 | 124篇 |
1983年 | 127篇 |
1982年 | 144篇 |
1981年 | 139篇 |
1980年 | 118篇 |
1979年 | 56篇 |
1978年 | 72篇 |
1977年 | 61篇 |
1976年 | 47篇 |
1975年 | 36篇 |
1974年 | 39篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
11.
12.
13.
Michelle Linda Ferderbar Thomas E. Doyle Reza Samavi David Koff 《Journal l'Association canadienne des radiologistes》2019,70(2):119-124
Several regulatory bodies have agreed that low-dose radiation used in medical imaging is a weak carcinogen that follows a linear, non-threshold model of cancer risk. While avoiding radiation is the best course of action to mitigate risk, computed tomography (CT) scans are often critical for diagnosis. In addition to the as low as reasonably achievable principle, a more concrete method of dose reduction for common CT imaging exams is the use of a diagnostic reference level (DRL). This paper examines Canada's national DRL values from the recent CT survey and compares it to published provincial DRLs as well as the DRLs in the United Kingdom and the United States of America for the 3 most common CT exams: head, chest, and abdomen/pelvis. Canada compares well on the international scale, but it should consider using more electronic dose monitoring solutions to create a culture of dose optimization. 相似文献
14.
15.
16.
17.
18.
Juin Fok-Seang Linda C. Smith-Thomas Sally Meiners Elizabeth Muir Jian-Sheng Du Elizabeth Housden Alan R. Johnson Andreas Faissner Herbert M. Geller Roger J. Keynes John H. Rogers James W. Fawcett 《Brain research》1995,689(2):207
The adult mammalian central nervous system (CNS) lacks the capacity to support axonal regeneration. There is increasing evidence to suggest that astrocytes, the major glial population in the CNS, may possess both axon-growth promoting and axon-growth inhibitory properties and the latter may contribute to the poor regenerative capacity of the CNS. In order to examine the molecular differences between axon-growth permissive and axon-growth inhibitory astrocytes, a panel of astrocyte cell lines exhibiting a range of axon-growth promoting properties was generated and analysed. No clear correlation was found between the axon-growth promoting properties of these astrocyte cell lines with: (i) the expression of known neurite-outgrowth promoting molecules such as laminin, fibronectin andN-cadherin; (ii) the expression of known inhibitory molecules such tenascin and chondroitin sulphate proteoglycan; (iii) plasminogen activator and plasminogen activator inhibitor activity; and (iv) growth cone collapsing activity. EM studies on aggregates formed from astrocyte cell lines, however, revealed the presence of an abundance of extracellular matrix material associated with the more inhibitory astrocyte cell lines. When matrix deposited by astrocyte cell lines was assessed for axon-growth promoting activity, matrix from permissive lines was found to be a good substrate, whereas matrix from the inhibitory astrocyte lines was a poor substrate for neuritic growth. Our findings, taken together, suggest that the functional differences between the permissive and the inhibitory astrocyte cell lines reside largely with the ECM. 相似文献
19.
20.
The incidence of lower urinary tract dysfunction increases during the climacteric, and there is embryological, biochemical and epidemiologic evidence to suggest that depleted estrogen status is at least partially responsible. Twelve climacteric women underwent full assessment before and 1 year after treatment with a 50 mg subcutaneous estradiol implant +5 mg norethisterone for 7 days per month. Assessment consisted of a symptoms questionnaire, midstream urine sample, uroflowmetry, videocystourethrography with pressure flow studies, and urethral pressure profilometry. Subjectively, only the symptom of nocturia significantly improved. There was no change in flow variables but there was a significant decrease in residual urine and the degree of bladder base descent. Cystometric capacity was slightly but significantly decreased, and two patients developed genuine stress incontinence whilst on treatment. Nonetheless, there was a significant improvement in urethral pressures at rest but not under stress. This effect was predominantly in the proximal urethra. These data do not support the contention that estrogen replacement therapy is beneficial for lower urinary tract dysfunction during the climacteric. 相似文献